Clinical Trial

ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.

Study acronym: ALaCART
Unknown Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 9, 2021 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The objective of this study is to assess the safety and efficacy of a immunophenotype-adapted approach using CAR T-cells in patients with high-risk, refractory or relapsed B-lineage acute lymphoblastic leukemia (B-ALL).
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT05038696
Lead Sponsor National University Hospital, Singapore
Conditions Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute Adult, Lymphoblastic Leukemia in Children, CAR, CAR T-Cell-Related Encephalopathy Syndrome
Enrollment 40 participants
Start Date 2021-04-28
Primary Completion 2026-05-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2021-09-09